Characterization of rhBMP-2 pharmacokinetics implanted with biomaterial carriers in the rat ectopic model
Recombinant human bone morphogenetic protein‐2 (rhBMP‐2) is a member of the bone morphogenetic protein family involved in de novo bone induction. Successful use of rhBMP‐2 requires implantation with a biomaterial which can act as a scaffold for cell invasion for osteoinduction and retains rhBMP‐2 at...
Gespeichert in:
| Veröffentlicht in: | Journal of biomedical materials research 1999-08, Vol.46 (2), p.193-202 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 202 |
|---|---|
| container_issue | 2 |
| container_start_page | 193 |
| container_title | Journal of biomedical materials research |
| container_volume | 46 |
| creator | Uludag, Hasan D'Augusta, Darren Palmer, Russ Timony, Greg Wozney, John |
| description | Recombinant human bone morphogenetic protein‐2 (rhBMP‐2) is a member of the bone morphogenetic protein family involved in de novo bone induction. Successful use of rhBMP‐2 requires implantation with a biomaterial which can act as a scaffold for cell invasion for osteoinduction and retains rhBMP‐2 at a site of implantation. This study was carried out to characterize rhBMP‐2 pharmacokinetics from a variety of biomaterial carriers in a rat ectopic model. Retention of rhBMP‐2 within carriers after 3 h was variable among the carriers (range, 75–10%), with collagenous sponges retaining the highest fraction of implanted dose. A gradual loss of rhBMP‐2 was subsequently observed, the kinetics of which was strongly dependent on the implanted carrier. Collagenous carriers were observed to lose rhBMP‐2 gradually from the implant site, whereas some of the mineral‐based carriers retained a fraction of implanted rhBMP‐2 within the implants. These differences in protein pharmacokinetics among carriers, in addition to their physicochemical nature, are expected to affect the biological activity of implanted rhBMP‐2. © 1999 John Wiley & Sons, Inc. J Biomed Mater, 46, 193–202, 1999. |
| doi_str_mv | 10.1002/(SICI)1097-4636(199908)46:2<193::AID-JBM8>3.0.CO;2-1 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69842977</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>69842977</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5358-31ca8a77baa01da2176be913a273e3ca5d797c27aa69b3967d478c3cc9bdf5953</originalsourceid><addsrcrecordid>eNqFkVFv0zAUhSMEYmXwF5AfENoeUuzcJra7CWkLbBTaFcQQEi_WjeOoZklT7FRj_HocUm1IIO3J1_a53z26J4qOGR0zSpNXB59n-eyQUcnjSQbZAZNSUnE4yabJMZMwnZ7M3sTvTxfiNYzpOF8eJTF7EI1uGx5Go4BhsQQ62YueeP-dUiolsMfRHqPAA46PIpuv0KHujLO_sLPtmrQVcavTxcc4IZvw16Bur-zadFZ7YptNjevOlOTaditS2LbBvhVrotE5a1zQrEm3MsRhR4zu2o3VpGlLUz-NHlVYe_Nsd-5HX87eXubv4vnyfJafzGOdQipiYBoFcl4gUlZiwnhWGMkAEw4GNKYll1wnHDGTBciMlxMuNGgti7JKZQr70cuBu3Htj63xnWqs16YOxk279SqTYpJIzu8VMg6CCkmD8HIQatd670ylNs426G4Uo6rPSqk-K9WvXvWrV0NWoVZJqEGpkJXqs1KgqMqX_XPAPt_N3xaNKf-CDuEEwYudAL3GunK41tbf6QQIIeHO3rWtzc0_3u6x9h9nf-4BGw9Y6zvz8xaL7kplHHiqvl6cq8XFt3n-4dOZyuE3dFzLXw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17380890</pqid></control><display><type>article</type><title>Characterization of rhBMP-2 pharmacokinetics implanted with biomaterial carriers in the rat ectopic model</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Uludag, Hasan ; D'Augusta, Darren ; Palmer, Russ ; Timony, Greg ; Wozney, John</creator><creatorcontrib>Uludag, Hasan ; D'Augusta, Darren ; Palmer, Russ ; Timony, Greg ; Wozney, John</creatorcontrib><description>Recombinant human bone morphogenetic protein‐2 (rhBMP‐2) is a member of the bone morphogenetic protein family involved in de novo bone induction. Successful use of rhBMP‐2 requires implantation with a biomaterial which can act as a scaffold for cell invasion for osteoinduction and retains rhBMP‐2 at a site of implantation. This study was carried out to characterize rhBMP‐2 pharmacokinetics from a variety of biomaterial carriers in a rat ectopic model. Retention of rhBMP‐2 within carriers after 3 h was variable among the carriers (range, 75–10%), with collagenous sponges retaining the highest fraction of implanted dose. A gradual loss of rhBMP‐2 was subsequently observed, the kinetics of which was strongly dependent on the implanted carrier. Collagenous carriers were observed to lose rhBMP‐2 gradually from the implant site, whereas some of the mineral‐based carriers retained a fraction of implanted rhBMP‐2 within the implants. These differences in protein pharmacokinetics among carriers, in addition to their physicochemical nature, are expected to affect the biological activity of implanted rhBMP‐2. © 1999 John Wiley & Sons, Inc. J Biomed Mater, 46, 193–202, 1999.</description><identifier>ISSN: 0021-9304</identifier><identifier>EISSN: 1097-4636</identifier><identifier>DOI: 10.1002/(SICI)1097-4636(199908)46:2<193::AID-JBM8>3.0.CO;2-1</identifier><identifier>PMID: 10379997</identifier><identifier>CODEN: JBMRBG</identifier><language>eng</language><publisher>New York: John Wiley & Sons, Inc</publisher><subject>Animals ; Biocompatible Materials ; Biological and medical sciences ; biomaterial ; Bone and Bones - cytology ; Bone Development - drug effects ; Bone Morphogenetic Protein 2 ; Bone Morphogenetic Proteins - administration & dosage ; Bone Morphogenetic Proteins - pharmacokinetics ; Bones, joints and connective tissue. Antiinflammatory agents ; CHO Cells ; Collagen ; Cricetinae ; Drug Carriers ; Drug Implants ; Half-Life ; Humans ; Iodine Radioisotopes ; Medical sciences ; Orthopedic surgery ; osteoinduction ; pharmacokinetics ; Pharmacology. Drug treatments ; protein delivery ; Rats ; Recombinant Proteins - administration & dosage ; Recombinant Proteins - pharmacokinetics ; rhBMP-2 ; Sulfur Radioisotopes ; Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases ; Transforming Growth Factor beta</subject><ispartof>Journal of biomedical materials research, 1999-08, Vol.46 (2), p.193-202</ispartof><rights>Copyright © 1999 John Wiley & Sons, Inc.</rights><rights>1999 INIST-CNRS</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c5358-31ca8a77baa01da2176be913a273e3ca5d797c27aa69b3967d478c3cc9bdf5953</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2F%28SICI%291097-4636%28199908%2946%3A2%3C193%3A%3AAID-JBM8%3E3.0.CO%3B2-1$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2F%28SICI%291097-4636%28199908%2946%3A2%3C193%3A%3AAID-JBM8%3E3.0.CO%3B2-1$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1416,27923,27924,45573,45574</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1838893$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10379997$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Uludag, Hasan</creatorcontrib><creatorcontrib>D'Augusta, Darren</creatorcontrib><creatorcontrib>Palmer, Russ</creatorcontrib><creatorcontrib>Timony, Greg</creatorcontrib><creatorcontrib>Wozney, John</creatorcontrib><title>Characterization of rhBMP-2 pharmacokinetics implanted with biomaterial carriers in the rat ectopic model</title><title>Journal of biomedical materials research</title><addtitle>J. Biomed. Mater. Res</addtitle><description>Recombinant human bone morphogenetic protein‐2 (rhBMP‐2) is a member of the bone morphogenetic protein family involved in de novo bone induction. Successful use of rhBMP‐2 requires implantation with a biomaterial which can act as a scaffold for cell invasion for osteoinduction and retains rhBMP‐2 at a site of implantation. This study was carried out to characterize rhBMP‐2 pharmacokinetics from a variety of biomaterial carriers in a rat ectopic model. Retention of rhBMP‐2 within carriers after 3 h was variable among the carriers (range, 75–10%), with collagenous sponges retaining the highest fraction of implanted dose. A gradual loss of rhBMP‐2 was subsequently observed, the kinetics of which was strongly dependent on the implanted carrier. Collagenous carriers were observed to lose rhBMP‐2 gradually from the implant site, whereas some of the mineral‐based carriers retained a fraction of implanted rhBMP‐2 within the implants. These differences in protein pharmacokinetics among carriers, in addition to their physicochemical nature, are expected to affect the biological activity of implanted rhBMP‐2. © 1999 John Wiley & Sons, Inc. J Biomed Mater, 46, 193–202, 1999.</description><subject>Animals</subject><subject>Biocompatible Materials</subject><subject>Biological and medical sciences</subject><subject>biomaterial</subject><subject>Bone and Bones - cytology</subject><subject>Bone Development - drug effects</subject><subject>Bone Morphogenetic Protein 2</subject><subject>Bone Morphogenetic Proteins - administration & dosage</subject><subject>Bone Morphogenetic Proteins - pharmacokinetics</subject><subject>Bones, joints and connective tissue. Antiinflammatory agents</subject><subject>CHO Cells</subject><subject>Collagen</subject><subject>Cricetinae</subject><subject>Drug Carriers</subject><subject>Drug Implants</subject><subject>Half-Life</subject><subject>Humans</subject><subject>Iodine Radioisotopes</subject><subject>Medical sciences</subject><subject>Orthopedic surgery</subject><subject>osteoinduction</subject><subject>pharmacokinetics</subject><subject>Pharmacology. Drug treatments</subject><subject>protein delivery</subject><subject>Rats</subject><subject>Recombinant Proteins - administration & dosage</subject><subject>Recombinant Proteins - pharmacokinetics</subject><subject>rhBMP-2</subject><subject>Sulfur Radioisotopes</subject><subject>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</subject><subject>Transforming Growth Factor beta</subject><issn>0021-9304</issn><issn>1097-4636</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkVFv0zAUhSMEYmXwF5AfENoeUuzcJra7CWkLbBTaFcQQEi_WjeOoZklT7FRj_HocUm1IIO3J1_a53z26J4qOGR0zSpNXB59n-eyQUcnjSQbZAZNSUnE4yabJMZMwnZ7M3sTvTxfiNYzpOF8eJTF7EI1uGx5Go4BhsQQ62YueeP-dUiolsMfRHqPAA46PIpuv0KHujLO_sLPtmrQVcavTxcc4IZvw16Bur-zadFZ7YptNjevOlOTaditS2LbBvhVrotE5a1zQrEm3MsRhR4zu2o3VpGlLUz-NHlVYe_Nsd-5HX87eXubv4vnyfJafzGOdQipiYBoFcl4gUlZiwnhWGMkAEw4GNKYll1wnHDGTBciMlxMuNGgti7JKZQr70cuBu3Htj63xnWqs16YOxk279SqTYpJIzu8VMg6CCkmD8HIQatd670ylNs426G4Uo6rPSqk-K9WvXvWrV0NWoVZJqEGpkJXqs1KgqMqX_XPAPt_N3xaNKf-CDuEEwYudAL3GunK41tbf6QQIIeHO3rWtzc0_3u6x9h9nf-4BGw9Y6zvz8xaL7kplHHiqvl6cq8XFt3n-4dOZyuE3dFzLXw</recordid><startdate>199908</startdate><enddate>199908</enddate><creator>Uludag, Hasan</creator><creator>D'Augusta, Darren</creator><creator>Palmer, Russ</creator><creator>Timony, Greg</creator><creator>Wozney, John</creator><general>John Wiley & Sons, Inc</general><general>John Wiley & Sons</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>199908</creationdate><title>Characterization of rhBMP-2 pharmacokinetics implanted with biomaterial carriers in the rat ectopic model</title><author>Uludag, Hasan ; D'Augusta, Darren ; Palmer, Russ ; Timony, Greg ; Wozney, John</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5358-31ca8a77baa01da2176be913a273e3ca5d797c27aa69b3967d478c3cc9bdf5953</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Animals</topic><topic>Biocompatible Materials</topic><topic>Biological and medical sciences</topic><topic>biomaterial</topic><topic>Bone and Bones - cytology</topic><topic>Bone Development - drug effects</topic><topic>Bone Morphogenetic Protein 2</topic><topic>Bone Morphogenetic Proteins - administration & dosage</topic><topic>Bone Morphogenetic Proteins - pharmacokinetics</topic><topic>Bones, joints and connective tissue. Antiinflammatory agents</topic><topic>CHO Cells</topic><topic>Collagen</topic><topic>Cricetinae</topic><topic>Drug Carriers</topic><topic>Drug Implants</topic><topic>Half-Life</topic><topic>Humans</topic><topic>Iodine Radioisotopes</topic><topic>Medical sciences</topic><topic>Orthopedic surgery</topic><topic>osteoinduction</topic><topic>pharmacokinetics</topic><topic>Pharmacology. Drug treatments</topic><topic>protein delivery</topic><topic>Rats</topic><topic>Recombinant Proteins - administration & dosage</topic><topic>Recombinant Proteins - pharmacokinetics</topic><topic>rhBMP-2</topic><topic>Sulfur Radioisotopes</topic><topic>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</topic><topic>Transforming Growth Factor beta</topic><toplevel>online_resources</toplevel><creatorcontrib>Uludag, Hasan</creatorcontrib><creatorcontrib>D'Augusta, Darren</creatorcontrib><creatorcontrib>Palmer, Russ</creatorcontrib><creatorcontrib>Timony, Greg</creatorcontrib><creatorcontrib>Wozney, John</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of biomedical materials research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Uludag, Hasan</au><au>D'Augusta, Darren</au><au>Palmer, Russ</au><au>Timony, Greg</au><au>Wozney, John</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Characterization of rhBMP-2 pharmacokinetics implanted with biomaterial carriers in the rat ectopic model</atitle><jtitle>Journal of biomedical materials research</jtitle><addtitle>J. Biomed. Mater. Res</addtitle><date>1999-08</date><risdate>1999</risdate><volume>46</volume><issue>2</issue><spage>193</spage><epage>202</epage><pages>193-202</pages><issn>0021-9304</issn><eissn>1097-4636</eissn><coden>JBMRBG</coden><abstract>Recombinant human bone morphogenetic protein‐2 (rhBMP‐2) is a member of the bone morphogenetic protein family involved in de novo bone induction. Successful use of rhBMP‐2 requires implantation with a biomaterial which can act as a scaffold for cell invasion for osteoinduction and retains rhBMP‐2 at a site of implantation. This study was carried out to characterize rhBMP‐2 pharmacokinetics from a variety of biomaterial carriers in a rat ectopic model. Retention of rhBMP‐2 within carriers after 3 h was variable among the carriers (range, 75–10%), with collagenous sponges retaining the highest fraction of implanted dose. A gradual loss of rhBMP‐2 was subsequently observed, the kinetics of which was strongly dependent on the implanted carrier. Collagenous carriers were observed to lose rhBMP‐2 gradually from the implant site, whereas some of the mineral‐based carriers retained a fraction of implanted rhBMP‐2 within the implants. These differences in protein pharmacokinetics among carriers, in addition to their physicochemical nature, are expected to affect the biological activity of implanted rhBMP‐2. © 1999 John Wiley & Sons, Inc. J Biomed Mater, 46, 193–202, 1999.</abstract><cop>New York</cop><pub>John Wiley & Sons, Inc</pub><pmid>10379997</pmid><doi>10.1002/(SICI)1097-4636(199908)46:2<193::AID-JBM8>3.0.CO;2-1</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0021-9304 |
| ispartof | Journal of biomedical materials research, 1999-08, Vol.46 (2), p.193-202 |
| issn | 0021-9304 1097-4636 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_69842977 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Animals Biocompatible Materials Biological and medical sciences biomaterial Bone and Bones - cytology Bone Development - drug effects Bone Morphogenetic Protein 2 Bone Morphogenetic Proteins - administration & dosage Bone Morphogenetic Proteins - pharmacokinetics Bones, joints and connective tissue. Antiinflammatory agents CHO Cells Collagen Cricetinae Drug Carriers Drug Implants Half-Life Humans Iodine Radioisotopes Medical sciences Orthopedic surgery osteoinduction pharmacokinetics Pharmacology. Drug treatments protein delivery Rats Recombinant Proteins - administration & dosage Recombinant Proteins - pharmacokinetics rhBMP-2 Sulfur Radioisotopes Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases Transforming Growth Factor beta |
| title | Characterization of rhBMP-2 pharmacokinetics implanted with biomaterial carriers in the rat ectopic model |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T09%3A14%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Characterization%20of%20rhBMP-2%20pharmacokinetics%20implanted%20with%20biomaterial%20carriers%20in%20the%20rat%20ectopic%20model&rft.jtitle=Journal%20of%20biomedical%20materials%20research&rft.au=Uludag,%20Hasan&rft.date=1999-08&rft.volume=46&rft.issue=2&rft.spage=193&rft.epage=202&rft.pages=193-202&rft.issn=0021-9304&rft.eissn=1097-4636&rft.coden=JBMRBG&rft_id=info:doi/10.1002/(SICI)1097-4636(199908)46:2%3C193::AID-JBM8%3E3.0.CO;2-1&rft_dat=%3Cproquest_cross%3E69842977%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=17380890&rft_id=info:pmid/10379997&rfr_iscdi=true |